Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endo-metrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immu-notherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive bio-markers of response to select patients most or at least likely to benefit from those treatments.

Tronconi, F., Nero, C., Giudice, E., Salutari, V., Musacchio, L., Ricci, C., Carbone, M. V., Ghizzoni, V., Perri, M. T., Camarda, F., Gentile, M., Berardi, R., Scambia, G., Lorusso, D., Advanced and recurrent endometrial cancer: State of the art and future perspectives, <<CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY>>, 2022; (180): 1-13. [doi:10.1016/j.critrevonc.2022.103851] [https://hdl.handle.net/10807/232471]

Advanced and recurrent endometrial cancer: State of the art and future perspectives

Nero, Camilla;Giudice, Elena;Salutari, Vanda;Ricci, Caterina;Carbone, Maria Vittoria;Perri, Maria Teresa;Camarda, Floriana;Scambia, Giovanni;Lorusso, Domenica
2022

Abstract

Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endo-metrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immu-notherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive bio-markers of response to select patients most or at least likely to benefit from those treatments.
2022
Inglese
Tronconi, F., Nero, C., Giudice, E., Salutari, V., Musacchio, L., Ricci, C., Carbone, M. V., Ghizzoni, V., Perri, M. T., Camarda, F., Gentile, M., Berardi, R., Scambia, G., Lorusso, D., Advanced and recurrent endometrial cancer: State of the art and future perspectives, <<CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY>>, 2022; (180): 1-13. [doi:10.1016/j.critrevonc.2022.103851] [https://hdl.handle.net/10807/232471]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/232471
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact